4/23
01:33 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
4/23
01:33 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
4/23
01:10 pm
ntla
Rating for NTLA
Low
Report
Rating for NTLA
4/23
01:10 pm
ntla
Rating for NTLA
Low
Report
Rating for NTLA
2/23
01:33 pm
ntla
Rating for NTLA
Low
Report
Rating for NTLA
2/23
01:33 pm
ntla
Rating for NTLA
Low
Report
Rating for NTLA
2/23
01:33 pm
ntla
Rating for NTLA
Low
Report
Rating for NTLA
2/23
09:53 am
ntla
Rating for NTLA
Low
Report
Rating for NTLA
2/15
06:08 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
2/15
06:08 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
2/15
07:17 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
2/15
07:17 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
2/15
06:29 am
ntla
Rating for NTLA
Low
Report
Rating for NTLA
2/15
06:29 am
ntla
Rating for NTLA
Low
Report
Rating for NTLA
2/14
04:16 pm
ntla
Intellia Therapeutics initiated with neutral view at Wolfe Research
Low
Report
Intellia Therapeutics initiated with neutral view at Wolfe Research
2/14
04:16 pm
ntla
Intellia Therapeutics initiated with neutral view at Wolfe Research
Low
Report
Intellia Therapeutics initiated with neutral view at Wolfe Research